MDS Sciex Says Q4 Organic Revenues Inched Up 1 Percent | GenomeWeb
NEW YORK (GenomeWeb News) — MDS today reported that fourth-quarter revenue for its Sciex division declined 5.5 percent to $69 million from $73 million year over year.
The company blamed the decline on currency effects but said organic revenues were up 1 percent.
MDS said Sciex’s organic increases came from growth in the small-molecule business and high-end triple quad and trap products, and from growth in India and China.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.